Background: Vitiligo is a frequent hypopigmentary disorder that can impact both adults and children and has significant psychosocial consequences due to its leopard skin-like look. Vitiligo must be treated and studied more frequently, even if it is not life-threatening or asymptomatic.
Objective: A comparative intra-individual study was conducted to evaluate the efficacy of intralesional methotrexate against intralesional triamcinolone acetonide in the therapy of localized non-segmental vitiligo.
Patients and methods: Our study was carried out on 30 patients complaining of vitiligo from August 2021 to January 2022. Thirty subjects with two comparable patches, one of them was randomly selected and treated with Intralesional Methotrexate and the other was treated with Intralestional Triamcinolone Acetonide . Patients were selected from out-patient clinic of Dermatology, Venereology and Andrology Department of Al-Azhar University Hospitals.
Results: The present study showed improvement in Patches treated with Intralesional Methotrexate as excellent response in13.3% of patients, good response in 13.3% of patients, fair response in 10% of patients and poor response in 63.3% of patients. Improvement in Patches treated with Intralestional Triamcinolone Acetonide as excellent response in 13.3% of patients, good response in 13.3% of patients, fair response in 16.7% of patients and poor response in 56.7% of patients.
Conclusion: using Intralestional Methotrexate and intralesional Triamcinolone Acetonide considered a promising, safe and effective therapeutic options for localized vitiligo with no significant side effects.